The phenotypic resistance to ethambutol (EMB) in Mycobacterium tuberculosis with embB gene mutations is still unclear. This study was designed to better understand EMB resistance due to embB gene mutation. Sequencing analysis of the embB gene was performed for 124 EMBsusceptible and 93 EMB-resistant M. tuberculosis strains isolated from South Korea. The MIC was determined for EMB-susceptible M. tuberculosis strains with the embB mutation and wildtype on Lö wenstein-Jenson (LJ) solid medium in duplicate. Two (2.8 %) of 72 pan-susceptible, two (9.1 %) of 22 any-drug-resistant but EMB-susceptible, nine (30.0 %) of 30 multidrugresistant (MDR) but EMB-susceptible and 84 (90.3 %) of 93 EMB-resistant M. tuberculosis strains possessed embB mutations at various codons including 306, 319, 354, 360, 399, 405, 406, 459 and 497. Strains with embB mutations at codons 306, 354, 399, 405 and 497 had highly pronounced EMB resistance, while strains with mutations at codons 319 and 406 mutations were moderately resistant and those with an embB459 mutation were EMBsusceptible at the critical concentration (2.0 mg ml "1 ) on LJ solid medium. However, the mean MIC for strains with embB mutations (1.42 mg ml "1 ) was higher than that for strains without the embB mutation (1.0 mg ml "1 ) in EMB-susceptible M. tuberculosis isolates (P50.0052). Three novel embB mutations at codons 399, 405 and 459 were identified in this study. These results support the hypothesis that embB mutation except for a few specific mutation types may be the main cause of EMB resistance.
INTRODUCTION
Tuberculosis is a major global health problem (WHO, 2009) . The emergence of multidrug-resistant (MDR) tuberculosis and, more recently, of extensively drug-resistant tuberculosis, is widely considered to be a serious threat to global tuberculosis control (CDC, 2006; Migliori et al., 2007; Raviglione & Smith, 2007) . The control of tuberculosis remains one of the more elusive goals in medicine. Rapid detection of drug resistance is essential to design appropriate treatment regimens, prevent treatment failure and thus reduce the further spread of drug-resistant isolates.
Ethambutol (EMB) [dextro-2,29-(ethylenediimino)-di-1-butanol] is a narrow-spectrum antimycobacterial agent that is used for the treatment of tuberculosis. EMB is a first-line anti-tuberculosis agent that is especially important when used in drug combinations to prevent the emergence of drug resistance or to treat single drugresistant tuberculosis (WHO, 1997) . Further, streptomycin has been replaced by EMB as a key drug in the intensive phase of tuberculosis chemotherapy as it is less expensive and patient compliance is better with this drug (Rabarijaona et al., 1999) . This agent has been proposed to be an arabinose analogue; the specific target is likely to be an arabinosyltransferase, presumably a functionally important site. A two-gene locus (embAB) that encodes arabinosyltransferase has been studied to elucidate a potential mechanism of EMB resistance (Alcaide et al., 1997; Telenti et al., 1997) .
Amino acid replacements at position 306 of EmbB have been shown in many studies to be present in EMB-resistant, but not EMB-susceptible, organisms (Alcaide et al., 1997; Ramaswamy & Musser, 1998; Sreevatsan et al., 1997) . However, Mokrousov et al. (2002) detected mutations of embB306 in both EMB-susceptible and EMB-resistant strains. EMB is an important antimycobacterial drug as it enhances the effect of other companion drugs including aminoglycosides, rifamycins and quinolones. Moreover, this drug has also been shown to significantly decrease the levels of bacteraemia in patients with AIDS (Kemper et al., 1994) .
Consequently, mutations in codon 306 have been suggested as molecular markers for the rapid detection of EMB resistance (Lee et al., 2004; Plinke et al., 2006; Van Rie et al., 2001) . Furthermore, two recent studies demonstrated a clear causative relationship between embB306 point mutations and in vitro EMB resistance by allelic-exchange experiments (Safi et al., 2008; Starks et al., 2009) . Identification of additional mutations occurring in EMB-resistant organisms will be useful in further understanding the mechanisms of resistance to this primary anti-tuberculosis agent. In our study, we tried to understand EMB resistance in detail by studying its relationship with mutations in the embB gene.
METHODS
Strains. The strains were randomly selected from among M. tuberculosis isolates from pulmonary tuberculosis patients registered in public health centres of South Korea from 2005 to 2007 that were stored at the Korean Mycobacterial Resource Center (KMRC). We included 72 pan-susceptible, 22 EMB-susceptible with any drug resistance but non-MDR, 30 EMB-susceptible and MDR and 93 EMB-resistant with or without other drug resistances (Supplementary Table S1 in JMM Online). All strains had different IS6110 RFLP types, as performed by a standardized procedure described previously (Park et al., 2000) .
Drug susceptibility testing. Phenotypic drug susceptibility testing was performed against isoniazid (0.2 mg ml 21 ), rifampicin (40 mg ml 21 ), streptomycin (10 mg ml 21 ) and EMB (2 mg ml 21 ) in LJ medium using the absolute concentration method (Canetti et al., 1969) . The MICs of EMB were compared between pan-susceptible strains and EMB-susceptible but other-drug-resistant embB mutant strains.
Selected isolates were inoculated onto LJ medium containing various concentrations of EMB (0-32 mg ml 21 ). These strains were retested twice to obtain a mean EMB MIC for each strain.
PCR and sequencing. Primers were designed to target an 800 bp region of the embB gene encompassing codons 297-497 for analysis. A pair of primers, embB-F (59-GGT GAT ATT CGG CTT CCT-39) and embB-R (59-ATA GCG CGG TGA TCA AAA AG-39), was designed for the PCR. The embB306, -406 and -497 mutations have been found to be a main cause of EMB resistance. This study was focused on 800 bp of the hot spot region and excluded the possible mutations in the remaining region of the 3.3 kb embB gene.
In a total volume of 20 ml, PCR mixtures contained 500 mM KCl, 100 mM Tris/HCl (pH 9.0), 1 % Triton X-100, 200 mM deoxynucleoside triphosphates (dATP, dGTP, dTTP and dCTP), 10 pmol of each of the members of the primer pair, 1.5 mM MgCl 2 , 1 U Taq DNA polymerase (Qiagen) and 1 ml template DNA. After heating the mixture to 95 uC for 7 min, amplification was carried out in 35 sequential cycles with denaturation at 94 uC for 30 s, primer annealing at 56 uC for 30 s and primer extension at 72 uC for 1 min. The last extension step was performed by incubation at 72 uC for 7 min. The DNA fragments were routinely examined on agarose gels stained with ethidium bromide. The direct sequencing of the embB gene with PCR products was performed using a BigDye Terminator v3.1 Cycle Sequencing kit and analysed with an ABI 3730XL genetic analyser.
Statistical analysis. Statistical analyses were performed using SAS version 9.1.3. We performed the trend analysis using Bartholomew's test, which is a more powerful test than the chi-square test for ordered data, and also employed the Wilcoxon rank sum test to analyse MIC differences by the embB mutation.
RESULTS
Analysis of the embB mutation in EMB-susceptible M. tuberculosis strains A total of 124 EMB-susceptible and 93 EMB-resistant M. tuberculosis strains were analysed to determine a potential relationship between EMB resistance and embB mutation. Two (2.8 %) of 72 pan-susceptible M. tuberculosis strains possessed embB mutations at codons 360 (silent mutation, Val to Val) and 459 (Gly to Asp) ( Table 1 ). These two strains revealed MICs of 1.25 mg ml 21 and 0.75 mg ml 21 , which were not higher than the MICs for pan-susceptible M. tuberculosis strains without embB mutation (Table 2) . Two strains (9.1 %) out of 22 any-drug-resistant EMBsusceptible M. tuberculosis strains had embB mutations (Table 1) . These strains were rifampicin mono-resistant with an embB406 mutation. MICs for these strains were higher than those for pan-susceptible strains (Table 2) .
Nine (30.0 %) of 30 MDR but EMB-susceptible M. tuberculosis strains revealed various embB mutations such as Met306Ile, Met306Val, Tyr319Ser, Gly406Asp, Gly406Ala and Gln497Lys (Table 2) . Only one strain (3.8 %) was EMBsusceptible out of 26 strains with Met306Ile mutation (Table  1) . Two (6.3 %) of 32 strains with Met306Val mutation were MDR but EMB-susceptible. One (50 %) of two strains with Tyr319Ser mutation was EMB-susceptible and had a higher MIC (1.5 mg ml
21
) than the MICs for pan-susceptible strains.
Four (66.7 %) of six Gly406Asp mutants (excluding embB405, 406 simultaneous mutant) and two (66.7 %) of three Gly406Ala mutants were EMB-susceptible. embB406 mutation seems to be less associated with EMB resistance at the LJ medium critical concentration (2.0 mg ml 21 ) in this study. One (50.0 %) of two strains with a Gln497Lys mutation was EMB-susceptible. However, all other Gln497Pro and Gln497Arg mutants revealed EMB resistance (Table 1) . embB mutation rate according to drug resistance
The embB mutation rate for 93 EMB-resistant M. tuberculosis strains was 90.3 %, but 2.8 % in pan-susceptible strains, 9.1 % in any-drug-resistant but non-MDR strains and 30.0 % in MDR but EMB-susceptible M. tuberculosis strains ( Table 1 ). The proportion of strains with embB mutations increased with increasing anti-tuberculous drug resistance (i.e. in the order of pan-susceptible, any-drugresistant EMB-susceptible, MDR EMB-susceptible and EMB-resistant M. tuberculosis strains) as shown by Bartholomew's test (a statistical value of 141.65, higher than the critical value, which is in the range 3.805-4.354).
In the 93 EMB-resistant strains, the embB306 mutation was most prevalent (67.9 % of strains), followed by the embB497 mutation (14.3 %) and the embB406 mutation (7.1 %) ( Table 3 ). The rate of embB mutation in EMB-resistant strains also increased in proportion to the number of drugs that the strains were resistant to (a statistical value of 76.21, higher than the critical value of 3.82 by Bartholomew's test).
Comparison of MICs
The mean MICs for six pan-susceptible strains versus 11 EMB-susceptible strains but with other drug resistances and embB mutations at codons 306, 319, 406 or 497 were 1.0 mg ml 21 and 1.42 mg ml
21
, respectively. This result shows that the embB mutation in the drug-resistant M. tuberculosis strains is associated with increased MICs of EMB (Wilcoxon statistic529.0, P-value50.0052), even though the critical concentration for EMB-susceptible strains was 2.0 mg ml 21 .
Novel embB mutations and EMB susceptibility
We identified novel embB mutations at codons 399, 405 and 459. We found two Asn399Thr and two Glu405Asp embB mutations in EMB-resistant M. tuberculosis strains. One Gly459Asp embB mutation was found in pan-susceptible M. tuberculosis strains.
DISCUSSION
The ever-increasing burden of drug resistance is a serious concern in the world, particularly for patients with M. tuberculosis infection. This mycobacterium uses various mechanisms to evade killing by therapeutic drugs, including mutations in genes that encode drug target proteins (Cole et al., 1998; Morris et al., 1995; Musser, 1995; Shi et al., 2007) . The objective of this study was to identify mutations in a drug target gene in strains of M. tuberculosis prevalent among the Korean population. embB gene mutation was believed to be the main cause of EMB resistance in M. tuberculosis. However, the relationship between embB gene mutation and EMB resistance is controversial because of embB mutation in EMB-susceptible M. tuberculosis strains (Mokrousov et al., 2002; Lee et al., 2004; Van Rie et al., 2001; Shi et al., 2007; Hazbó n et al., 2005) .
Hazbó n et al. (2005) reported that 46 of 100 embB306 mutants were EMB-susceptible while 54 were EMB-resistant. After retesting, a few of the mutants were reclassified from susceptible to resistant. The EMB MICs for the embB306 mutants ranged from ,1 to .32 mg ml 21 (Hazbó n et al., 2005) . embB306 mutation was considered a common polymorphism with no relation to EMB resistance by Srivastava et al. (2009) . TAT-GAT 1 Tyr319Ser
TAT
CAG-CGG 9 Mutation total 2 (2. Depending upon mutation site or type, EMB resistance was found to be different. We found two embB mutations among 72 pan-susceptible M. tuberculosis strains. One of the two strains had a synonymous mutation at codon 360, which did not affect EMB resistance. The second pansusceptible strain had a Gly459Asp mutation, which is a novel mutation. However, this mutation also did not affect EMB resistance. embB mutation in pan-susceptible strains in particular may not affect EMB resistance. Similar to our results, Hazbó n et al. Only three MDR isolates (5.0 %) out of 60 embB306 mutants were EMB-susceptible in this study. Even though we also detected the embB306 mutation in EMB-susceptible clinical isolates, an embB306 substitution experiment from wildtype to mutation type proved that embB306 mutation increased the EMB MIC (Safi et al., 2008; Starks et al., 2009) . Safi et al. (2008) found that the substitution at embB306 did not affect rifampicin or isoniazid MICs. Further, we found that six (54.5 %) out of 11 embB406 mutant strains (excluding two strains, one with a synonymous mutation *DST, Drug-susceptibility testing; Pan-S, pan-susceptible; I, isoniazid-resistant; R, rifampicin-resistant; S, streptomycin-resistant; E, ethambutol-resistant. and another with an additional mutation at embB405) were EMB-susceptible (Table 1) . embB406 mutations have also been detected previously in EMB-susceptible isolates (Lee et al., 2004; Shi et al., 2011; Ramaswamy et al., 2004) . We found only one EMB-susceptible (7.7 %) strain out of 13 embB497 mutants. In a recent study, embB406 and allelic embB497 exchange increased the EMB MIC 3-3.5-fold and 6-fold, respectively, over that for the wild-type embB gene and these allelic exchanges did not affect the MIC of other anti-tuberculous drugs such as isoniazid or rifampicin (Safi et al., 2010) .
For the minor mutations, two of three embB319 mutants were EMB-resistant and another one was EMB-susceptible with MDR as shown in Table 2 . Likewise, the Tyr319Ser and Tyr319Asp mutations were found in EMB-resistant M. tuberculosis strains in previous reports (Plinke et al., 2006; Sugawara et al., 2005) . The Asp354Ala mutation revealed EMB resistance, which has been reported previously (Sekiguchi et al., 2007) .
In this study, three novel embB mutations (Asn399Thr, Glu405Asp and Gly459Asp) were detected. Though all three of the codon sites were also found in another study, those mutations produced different amino acids (Srivastava et al., 2009) . Among the three novel mutations, two (Asn399Thr and Glu405Asp) were associated with EMB resistance.
Our study further suggested that the proportion of strains with embB mutations increased with the increasing number of drug resistances in both EMB-susceptible and EMBresistant strains. This finding also agreed with those in other studies (Lee et al., 2004; Shi et al., 2011; Shen et al., 2007) .
Along with the above results, we found that the mean EMB MIC for embB-mutated EMB-susceptible strains was higher than that for pan-susceptible strains. This may be caused by the limitation of conventional drug susceptibility testing methods for EMB (Kim, 2005) . Kim (2005) reported that 90 % of probably EMB-susceptible strains and 30-50 % of probably EMB-resistant strains were inhibited at the critical concentration of 2.0 mg ml 21 on LJ solid medium.
However, we compared only the MICs for EMB-susceptible strains with those for pan-susceptible and other-drugresistant strains with the embB mutation, so we need further studies to compare the MICs of EMB in EMB-susceptible strains with and without the embB mutations.
In conclusion, the exact mechanism of EMB resistance is not yet clearly understood. Our data support that the embB mutation, except for a few specific mutations such as Gly459Asp, may be the main cause of EMB resistance.
